echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > More than 80% of patients' tumors have shrunk!

    More than 80% of patients' tumors have shrunk!

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On December 10, Infinity announced at the San Antonio Breast Cancer Symposium (SABCS) that the PI3Kγ inhibitor eganelisib combined with Atelizumab (Tecentriq) and Albumin Paclitaxel (Abraxane) as the first-line treatment of metastatic triple-negative breast cancer (TNBC) Updated data for the Phase II MARIO-3 study


    Eganelisib is a first-in-class highly selective oral PI3Kγ inhibitor


    At a median follow-up time of 9.


    The disease control rate (DCR) of PD-L1(+) tumor patients was 92.


    In PD-L1(+) patients, the median PFS of triple therapy was 11.


    The most common grade 3 or higher treatment-related TEAEs in the study were liver adverse reactions (18%); neutropenia (16%); skin-related adverse reactions (12%); fatigue, diarrhea, and peripheral sensations Neuropathy (6% each); vomiting and weight loss (2% each)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.